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Background: Although an increased risk of preeclampsia in pregnancies conceived by in vitro fertilization (IVF) has
been reported, it remains unknown whether IVF is associated with preeclampsia. In the present study, we sought to
investigate whether IVF is associated with preeclampsia in pregnant women using propensity score matching
analysis.
Methods: This study included 3,084 pregnant women who visited the National Center for Child Health and
Development before 20 weeks of gestation without hypertension or renal disease and delivered a singleton after
22 weeks of gestation between 2009 and 2011. Of the 3084 patients, 474 (15.4%) conceived by IVF (IVF group) and
2,610 (84.6%) conceived without IVF (non-IVF group). The propensity score for receiving IVF was estimated using
multiple logistic regression with 27 maternal and paternal variables. This model yielded a c-statistic of 0.852,
indicating a strong ability to differentiate between those conceiving with and without IVF. The association between
IVF and onset of preeclampsia was assessed by the propensity matched sample (pair of N = 474).
Results: There were 46 preeclampsia cases (1.5%) in the total study population, with a higher proportion of cases in
the IVF group (15 cases, 3.2%) than the non-IVF group (31 cases, 1.2%). Before propensity score matching, the IVF
group was 2.72 (95% confidence intervals [CI]: 1.46-5.08) times more likely to have preeclampsia when unadjusted,
and 2.32 (95% CI: 1.08-4.99) times more likely to have preeclampsia when adjusted for maternal and paternal
variables by logistic regression. After propensity score matching, the IVF group did not show a significantly greater
association with preeclampsia compared to the non-IVF group (odds ratio: 2.50, 95% CI: 0.49-12.89), although point
estimates showed a positive direction.
Conclusions: Propensity score matching analysis revealed that the association between IVF and preeclampsia
became weaker than when conventional adjustments are made in multivariate logistic regression analysis,
suggesting that the association between IVF and preeclampsia might be confounded by residual unmeasured
factors.
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Preeclampsia is a major obstetric problem worldwide that
causes significant maternal and perinatal morbidity and
mortality [1]. Several risk factors have been identified, in-
cluding advanced maternal age, primiparity, obesity,
chronic hypertension, renal disease, pre-gestational diabetes
mellitus, and autoimmune disease [2,3]. In addition, several* Correspondence: fujiwara-tk@ncchd.go.jp
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reproduction in any medium, provided the orstudies, including a systematic review and a meta-analysis,
have reported an increased risk of preeclampsia in pregnan-
cies conceived by in vitro fertilization (IVF) [4-7]. However,
these studies used limited adjustment for confounders, such
as age or parity. Thus, it remains unknown whether IVF
directly induces preeclampsia. A randomized control trial is
the ideal study design for investigating the impact of IVF
on preeclampsia, as it allows for adjusting for known
and unknown confounders. However, randomized as-
signment of IVF treatment is impossible in studies of
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which can minimize selection bias and confounding factors
in observational studies [8]. Estimating a propensity score
for IVF treatment and matching based on the score may
help determine whether IVF has a causal effect on pre-
eclampsia. To the best of our knowledge, no study has ex-
amined the association between IVF and the incidence of
preeclampsia using this statistical tool. Thus, we aimed to
investigate the association between IVF and the incidence
of preeclampsia by using a propensity score matching
model.Methods
Participants
We collected data of women who delivered between June
2009 and June 2011 at the National Center for Child Health
and Development (NCCHD) in Tokyo, Japan. This study
was approved by the NCCHD ethics committee. All
pregnant women were Japanese. Women who delivered
singleton neonates at ≥22 weeks of gestation without hyper-
tension or renal disease were enrolled in the study. In total,
we identified 3,084 women who met our study criteria
(eligible study sample), including 474 women who received
IVF (IVF group) and 2,610 women who did not (non-IVF
group). All 3,084 study participants had only one pregnancy
during this study period. Written informed consent was
not obtained from participants because the study involved
a secondary data analysis and such studies do not require
consent according to the NCCHD ethics committee.Assessment of preeclampsia
Preeclampsia was diagnosed after 20 weeks of gestation if
the pregnant woman had a blood pressure (BP) >140/
90 mmHg with proteinuria (>300 mg/24 hours). Early-
onset preeclampsia was defined as preeclampsia diagnosed
at <32 weeks of gestation, and late-onset preeclampsia was
defined as preeclampsia diagnosed at 32+ weeks of gesta-
tion. Severe preeclampsia was diagnosed as BP >160/
110 mmHg with proteinuria (>2 g/24 hours). Women re-
ceived routine prenatal checkups every four weeks up to
the 28th week of gestation, then every two weeks up to the
36th week of gestation, and then weekly up to delivery. At
each routine prenatal checkup, BP was measured in the sit-
ting position with the right arm held at heart level after a
five-minute rest period using an automated sphygmoman-
ometer (Omron BP203RVIII oscillometer, Nippon Colin,
Tokyo, Japan). Urine protein levels were assessed at each
prenatal checkup by a dipstick test of a single voided urine
sample. When the pregnant woman had an abnormal BP
(>140/90 mmHg) and urine test (1+ proteinuria on dip-
stick) at a routine prenatal checkup, she was hospitalized
for further evaluation of BP and urine protein and for
bed rest.Baseline characteristics and pregnancy outcomes
Maternal characteristics, including age, age at marriage,
parity, number of abortions, working status (full-time,
part-time, or housewife), height, weight before preg-
nancy, smoking and drinking during pregnancy, family
history of hypertension, mean systolic and diastolic BP
before 20 weeks of gestation, and underlying diseases
(central nervous system disease, cerebrovascular disease,
asthma, respiratory disease other than asthma, gastro-
intestinal disease, liver disease, hematologic disease, car-
diovascular disease, hyperthyroidism, hypothyroidism,
psychiatric disease, autoimmune disease, and preexisting
diabetes mellitus), were collected from the perinatal
database and medical charts. Paternal factors, including
age, age at marriage, height, weight, and smoking status,
were also collected. Missing data for continuous vari-
ables (maternal age at marriage, 28 cases [0.9%]; mater-
nal height, 25 cases [0.8%]; maternal weight, 26 cases
[0.8%]; paternal age at delivery, 219 cases [7.1%]; pater-
nal age at marriage, 239 cases [7.7%]; paternal height, 35
[1.1%]; and paternal weight, 35 [1.1%]) were substituted
with the average value of the variable. Missing data for
categorical variables were treated as dummy variables
(working status, 21 cases [0.7%]; family history of hyper-
tension, 235 cases [7.6%]; paternal smoking, 65 cases
[2.1%]).
Statistical analysis
Maternal and paternal characteristics were compared be-
tween the IVF and non-IVF groups using chi-squared or
Fisher’s exact tests for categorical variables and t-tests
for continuous variables.
Because IVF procedures were not randomly assigned in
this population, potential confounding and selection biases
were accounted for by developing a propensity score for the
IVF procedure. This propensity score was determined using
a multivariate logistic regression model adjusting for mater-
nal and paternal variables. These variables included those
listed above as baseline characteristics, except for drinking
during pregnancy and two types of underlying diseases
(central nervous system disease and cerebrovascular dis-
ease), due to their low frequency (<0.9%). Twenty-seven in-
dependent variables were thus used to determine the
propensity score. This model yielded a c-statistic of 0.852,
indicating a strong ability to differentiate between those
conceiving with and without IVF. The 474 IVF cases were
then matched one-to-n with 474 non-IVF cases with the
closest propensity score (nearest neighbor matching) [9,10].
The maximum difference in propensity score between each
matched pair was 0.057. Baseline characteristics and preg-
nancy outcomes in the eligible study sample (n = 3084) and
propensity-matched study sample (n = 948) are shown in
Table 1. Further, characteristics of preeclampsia (prevalence,
timing of onset, and severity), BP during mid- (28-32 weeks
Table 1 Baseline characteristics of the eligible study sample and propensity score matched sample
Eligible study sample
(n = 3084)












Age Year, mean (SD) 38.3 (3.3) 34.8 (4.2) <0.001 38.3 (3.3) 38.4 (3.3) 0.97
Age at marriage Year, mean (SD) 30.8 (4.1) 29.3 (3.8) <0.001 30.8 (4.1) 31.0 (4.1) 0.91
Parity 0, n (%) 370 (78.1) 1319 (50.5) <0.001 370 (78.1) 378 (79.8) 0.74
≥1, n (%) 104 (21.9) 1291 (49.5) 104 (21.9) 96 (20.3)
Abortion 0, n (%) 291 (61.4) 1767 (67.7) 0.009 291 (61.4) 304 (64.1) 0.39
1-2, n (%) 152 (32.1) 734 (28.1) 152 (32.1) 136 (28.7)
3≤, n (%) 31 (6.5) 109 (4.2) 31 (6.5) 34 (7.2)
Work Homemaker, n (%) 189 (39.9) 1122 (43.0) 0.31 189 (39.9) 190 (40.1) 0.93
Full time, n (%) 248 (52.3) 1268 (48.6) 248 (52.3) 238 (50.2)
Part time, n (%) 36 (7.6) 200 (7.7) 36 (7.6) 45 (9.5)
Missing, n (%) 1 (0.2) 20 (0.8) 1 (0.2) 1 (0.2)
Maternal health status
Height cm, mean (SD) 160.0 (5.4) 159.4 (5.2) 0.015 160.0 (5.4) 159.8 (5.1) 0.75
Weight before pregnancy kg, mean (SD) 52.4 (6.9) 51.5 (7.8) 0.011 52.4 (6.9) 52.0 (7.2) 0.74
Smoking during pregnancy Yes, n (%) 6 (1.3) 92 (3.5) 0.01 6 (1.3) 6 (1.3) 0.27
Drinking during pregnancy Yes, n (%) 0 (0) 11 (0.4) 0.39 0 (0) 0 (0) NA
Family history of hypertension Yes, n (%) 110 (23.2) 414 (15.9) <0.001 110 (23.2) 104 (21.9) 0.82
Systolic blood pressure <20 weeks of gestation mmHg, mean (SD) 110.4 (10.4) 108.4 (10.2) <0.001 110.4 (10.4) 110.9 (9.9) 0.75
Diastolic blood pressure <20 weeks of gestation mmHg, mean (SD) 64.8 (7.3) 62.8 (7.1) <0.001 64.8 (7.3) 65.0 (7.0) 0.86
Maternal medical complication
Central nervous system disease Yes, n (%) 0 (0) 27 (1.0) 0.016 0 (0) 1 (0.2) >0.99
Cerebrovascular disease Yes, n (%) 0 (0) 4 (0.2) >0.99 0 (0) 1 (0.2) >0.99
Asthma Yes, n (%) 13 (2.7) 92 (3.5) 0.49 13 (2.7) 9 (1.9) 0.29
Respiratory disease (except asthma) Yes, n (%) 2 (0.4) 3 (0.1) 0.17 2 (0.4) 4 (0.8) >0.99
Gastrointestinal disease Yes, n (%) 2 (0.4) 33 (1.3) 0.15 2 (0.4) 1 (0.2) 0.57
Liver disease Yes, n (%) 3 (0.6) 16 (0.6) >0.99 3 (0.6) 2 (0.4) 0.57
Hematologic disease Yes, n (%) 2 (0.4) 16 (0.6) >0.99 2 (0.4) 2 (0.4) >0.99
Cardiovascular disease Yes, n (%) 5 (1.1) 51 (2.0) 0.26 5 (1.1) 4 (0.8) 0.42
Hyperthyroidism Yes, n (%) 7 (1.5) 47 (1.8) 0.85 7 (1.5) 4 (0.8) >0.99
Hypothyroidism Yes, n (%) 13 (2.7) 70 (2.7) 0.88 13 (2.7) 14 (3.0) 0.29
Psychiatric disease Yes, n (%) 10 (2.1) 64 (2.5) 0.75 10 (2.1) 9 (1.9) >0.99
Autoimmune disease Yes, n (%) 9 (1.9) 55 (2.1) 0.86 9 (1.9) 6 (1.3) >0.99
Pre-existing diabetes mellitus Yes, n (%) 1 (0.2) 15 (0.6) 0.49 1 (0.2) 2 (0.4) 0.57
Paternal demographics
Age Year, mean (SD) 40.8 (4.8) 37.3 (4.9) <0.001 40.8 (4.8) 40.6 (4.8) 0.25
Age at marriage Year, mean (SD) 33.3 (5.3) 31.7 (4.8) <0.001 33.3 (5.3) 33.2 (5.6) 0.37
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Table 1 Baseline characteristics of the eligible study sample and propensity score matched sample (Continued)
Paternal health status
Partner's smoking status Yes, n (%) 136 (28.7) 705 (27.0) 0.31 136 (28.7) 140 (29.5) 0.84
Missing, n (%) 6 (1.3) 59 (2.3) 6 (1.3) 6 (1.3)
Partner's height cm, mean (SD) 172.7 (5.8) 173.1 (5.7) 0.16 172.7 (5.8) 173.4 (5.6) 0.10
Partner's weight kg, mean (SD) 69.6 (9.2) 69.8 (9.6) 0.70 69.6 (9.2) 70.1 (9.0) 0.64
IVF, in vitro fertilization; SD, standard deviation.
Chi-squared or Fisher’s exact tests for categorical variables and t-tests for continuous variables were used for the whole study population. Conditional logistic regression
for categorical variables and regression analysis using the fixed effect model for continuous variables were used in the propensity score matched sample.
Values in bold are significant at the p = 0.05 level.
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birth outcomes in the total eligible study sample (n = 3084)
and the propensity score matched sample (n = 948) were
compared. For comparison, chi-squared or Fisher’s exact
tests for categorical variables and t-tests for continuous var-
iables were used for the whole study population, and condi-
tional logistic regression for categorical variables and fixed
effect regression for continuous variables were used in the
propensity score matched sample.
To assess the association between IVF and preeclamp-
sia, we performed a logistic regression analysis in the ini-
tial eligible study sample (n = 3084), unadjusted and
adjusted for baseline characteristics, and performed a
conditional logistic regression analysis for the propensity
score matched sample (n = 948). All analyses were con-
ducted using STATA MP software (version 12.0; Stata
Corporation, College Station, TX).
Results
A comparison of baseline characteristics and pregnancy
outcomes between the IVF (n = 474) and non-IVF (n =
2,610) groups is shown in Table 1. Women in the IVF
group were older than those in the non-IVF group at the
time of first visit (38.3 vs. 34.8 years, p < 0.001) and at
marriage (30.8 vs. 29.3 years, p < 0.001). Women in the
IVF group were more likely to be nulliparous (78.1 vs.
50.5%, p < 0.001) and to have had abortions than those
in the non-IVF group (38.6 vs. 32.3%, p = 0.009). Women
in the IVF group were slightly taller and weighed more
than those in the non-IVF group (height, 160.0 vs.
159.4 cm, p = 0.015; weight, 52.4 vs. 51.5 kg, p = 0.011).
Furthermore, women in the IVF group were less likely
to smoke (1.3 vs. 3.5%, p = 0.01) but more likely to have
a family history of hypertension (23.2 vs. 15.9%, p < 0.001).
Mean BP before 20 weeks of gestation, which is considered
a proxy of baseline BP, was higher in the IVF group than in
the non-IVF group for both systolic (110.4 vs. 108.4 mmHg,
p < 0.001) and diastolic (64.8 vs. 62.8 mmHg, p < 0.001) BP.
The prevalence of underlying disease was not signifi-
cantly different between the IVF and non-IVF groups,
except for central nervous system disease. Partners of
women in the IVF group were older than those of
women in the non-IVF group at the time of first visit(40.8 vs. 37.3 years, p < 0.001) and at marriage (33.5 vs.
31.7 years, p < 0.001).
Baseline characteristics of the IVF and non-IVF groups
after propensity score matching (each n = 474) were not
significantly different. For example, maternal age for the
IVF and non-IVF groups was 38.3 and 38.4 years
(p = 0.97), respectively, and mean diastolic BP was 64.8
and 65.0 mmHg (p = 0.86) for the IVF and non-IVF
groups, respectively.
Table 2 shows the characteristics of preeclampsia and
BP during mid- and late-pregnancy in the IVF (n = 474)
and non-IVF (n = 2,610) groups. Preeclampsia was found
in 15 (3.2%) cases in the IVF group and 31 (1.2%) cases
in the non-IVF group. Among those who had pre-
eclampsia, the number of early onset (<32 weeks of ges-
tation) cases was two (13.3%) for the IVF group and
three (9.7%) for the non-IVF group, which was not sig-
nificantly different (p = 0.71). Further, the severity of pre-
eclampsia was not different between the IVF and non-
IVF groups: severe preeclampsia was found in eight
(53.3%) cases in the IVF group and 17 (54.8%) cases in
the non-IVF group (p = 0.92). Mean diastolic BP during
mid- and late-pregnancy was significantly higher in the
IVF group than in the non-IVF group (mid-pregnancy,
64.5 vs. 62.9 mmHg, p < 0.001; late-pregnancy, 67.4 vs.
65.9 mmHg, p < 0.001), while systolic BP during mid-
and late-pregnancy were not significantly different. Birth
weight was higher in the IVF group than in the non-IVF
group (3042.7 vs. 2988.1 g, p = 0.008), while gestational
age was not significantly different.
Table 2 also shows the characteristics of preeclampsia
and BP during mid- and late-pregnancy in the propensity
score matched sample (each n = 474). Although the preva-
lence of preeclampsia in the IVF group was higher than in
the non-IVF group (3.2% vs. 1.5%), the difference was not
significant after propensity matching (p = 0.27). Further,
mean diastolic BP during mid- and late-pregnancy was not
significantly different (mid-pregnancy, 64.5 vs. 64.3 mmHg,
p = 0.99; late-pregnancy, 67.4 vs. 67.1 mmHg, p = 0.69).
Birth weight also did not significantly differ.
Table 3 shows the odds ratios (ORs) of IVF for the risk
of preeclampsia in the total eligible study sample (n =
3,084), unadjusted and adjusted for baseline characteristics,
Table 2 Characteristics of preeclampsia and blood pressure during mid- and late-pregnancy












Prevalence n (%) 15 (3.2) 31 (1.2) 0.003 15 (3.2) 7 (1.5) 0.27
Timing (among those with preeclampsia)
Early onset (<32 weeks of gestation) n (%) 2 (13.3) 3 (9.7) 0.71 2 (13.3) 0 (0) 0.27
Late onset (≥32 weeks of gestation) n (%) 13 (86.7) 28 (90.3) 13 (86.7) 7 (100)
Severity (among those with preeclampsia)
Mild n (%) 7 (46.7) 14 (45.2) 0.92 7 (46.7) 3 (42.9) 0.27
Severe n (%) 8 (53.3) 17 (54.8) 8 (53.3) 4 (57.1)
Blood pressure
SBP during mid-pregnancyb mmHg, mean (SD) 109.0 (9.6) 108.2 (9.7) 0.10 109.0 (9.6) 109.3 (10.1) 0.42
DBP during mid-pregnancyb mmHg, mean (SD) 64.5 (6.6) 62.9 (6.9) <0.001 64.5 (6.6) 64.3 (7.3) 0.99
SBP during late-pregnancyc mmHg, mean (SD) 112.1 (9.6) 111.2 (9.7) 0.068 112.1 (9.6) 112.1 (9.0) 0.35
DBP during late-pregnancyc mmHg, mean (SD) 67.4 (6.7) 65.9 (7.0) <0.001 67.4 (6.7) 67.1 (6.8) 0.69
Birth outcomes
Birth weight g, mean (SD) 3042.7 (425.7) 2988.1 (408.0) 0.008 3042.7 (425.7) 3007.0 (414.0) 0.21
Gestational age weeks, mean (SD) 39.2 (1.6) 39.1 (1.6) 0.15 39.2 (1.6) 39.2 (1.7) 0.77
aPreeclampsia is considered severe if systolic blood pressure (BP) is ≥160 mmHg or diastolic BP is ≥110 mmHg on two occasions at least six hours apart while the
patient is on bed rest, or if proteinuria is ≥2 g/24 hours or ≥3 on dipstick in two random urine samples collected at least four hours apart.
bmid-pregnancy: 28-32 weeks of gestation.
clate-pregnancy: 34-38 weeks of gestation.
IVF, in vitro fertilization; SD, standard deviation; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Chi-squared or Fisher’s exact tests for categorical variables and t-tests for continuous variables were used for the whole study population. Conditional logistic
regression for categorical variables and regression analysis using the fixed effect model for continuous variables were used in the propensity score
matched sample.
Values in bold are significant at the p = 0.05 level.
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the unadjusted model using the eligible study sample, IVF
was a significant risk factor for preeclampsia (OR: 2.72,
95% confidence interval [CI]: 1.46–5.08, p = 0.002). After
adjusting for baseline maternal and paternal characteristics,
IVF was still significantly associated with preeclampsia
(OR: 2.32; 95% CI: 1.08–4.99, p = 0.031). However, in the
propensity score matched sample, IVF was not significantly
associated with preeclampsia, although the point estima-
tion of the risk of IVF for preeclampsia was in the same
positive direction as with the previous models (OR: 2.50,
95% CI: 0.49-12.89, p = 0.273).Table 3 Odds ratio of developing preeclampsia among patien
Model
Eligible study sample, unadjusted (n = 3084)
Eligible study sample, adjusted for baseline characteristicsa (n = 3084)
Propensity score matched sample (pair of n = 474)
aadjusted confounders were maternal characteristics (age, age at marriage, parity, n
and drinking during pregnancy, family history of hypertension, mean systolic and d
diseases such as central nervous system disease, cerebrovascular disease, asthma, h
and paternal characteristics (age, age at marriage, height, weight, and smoking stat
Multiple logistic regression was used for analysis.
Values in bold are significant at the p = 0.05 level.Discussion
In the present study, we used propensity score matching
analysis and adjusted for 27 known variables to simulate
random assignment of the IVF procedure. Using this
analysis, we found that women who conceived by IVF
were not at a significantly higher risk of preeclampsia
than women who conceived without IVF, although the
point estimation of the risk of IVF for preeclampsia was
positive (i.e. 2.50), suggesting that IVF may be weakly as-
sociated with preeclampsia.
To the best of our knowledge, this is the first study to
investigate the impact of IVF on preeclampsia usingts who had IVF




umber of abortions, working status, height, weight before pregnancy, smoking
iastolic blood pressure before 20-weeks gestational age, and underlying
yperthyroidism, hypothyroidism, psychiatric disease, and autoimmune disease)
us).
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of eight studies, Jackson et al. concluded that IVF was asso-
ciated with an increased risk of preeclampsia (OR: 1.55;
95% CI: 1.23–1.95) [4], although the point estimate of OR
was lower than that of our study, which might be due to
ethnic differences of the sample, or by chance. Moreover,
the studies used in the meta-analysis adjusted for only a
limited number of confounders, such as age and parity,
thereby limiting the ability to adjust for assignment bias in
the estimated effect. After this meta-analysis, several inves-
tigators demonstrated associations between IVF and pre-
eclampsia [5,6,11]. Shevell et al. adjusted for more
confounders (age, race, marital status, years of education,
prior preterm delivery with anomaly, body mass index
[BMI], smoking history, and bleeding during the current
pregnancy), and reported a significant association between
IVF and preeclampsia (OR: 2.7, 95% CI: 1.7–4.4) [5]. Our
study, which used propensity score matching with 27 vari-
ables, also showed a marginal impact of IVF on preeclamp-
sia, which is an important contribution to the literature.
Specifically, we demonstrated that IVF was not signifi-
cantly associated with preeclampsia, although the point
estimate of OR was 2.50, which implies that IVF is a risk
factor for preeclampsia. The lack of a significant associ-
ation might be due to the small sample size (n = 948);
however, attenuation of the point estimate of OR from
the unadjusted model (i.e., 2.72) to the propensity score
analysis (2.50) was substantial, suggesting that the asso-
ciation observed between IVF and preeclampsia in previ-
ous studies might have been due to confounders.
Further, the timing of onset of preeclampsia, severity
of preeclampsia, and BP during mid- and late-pregnancy
did not differ between the IVF and non-IVF groups.
These results suggest that IVF may not elevate BP or in-
duce preeclampsia because women with preeclampsia
have higher BP levels throughout pregnancy [12].
Macdonald-Wallis et al. reported that age, BMI, and par-
ity affected BP throughout pregnancy [13], but no single
risk factor elevated BP during only early pregnancy.
A plausible biological mechanism to explain how there
could be a causal relationship between IVF and preeclamp-
sia is unclear. Abnormal placentation is considered the pri-
mary stage of pathogenesis in preeclampsia [14]. In a
recent systematic review, several biological mechanisms by
which IVF may be associated with preeclampsia by abnor-
mal placentation have been proposed [7]. Transfer of the
conceptus into the uterine cavity and the effect of an al-
tered hormonal environment in the uterine myometrium
during the IVF procedure may interfere with the develop-
ment of the maternal-fetal interface. Additionally, as the
formation of the chorion is initiated in vitro in IVF preg-
nancies, the inherent difference in the nature of the pla-
centa may lead to abnormal placentation and diseased
placental vessels. Furthermore, inadequate utero-placentalcirculation may contribute to the association between IVF
and preeclampsia.
There are several limitations to our study. First, given our
observational study design, we could not completely avoid
selection biases and unknown confounding factors (e.g.,
personality and genetic traits) that existed before IVF treat-
ment. These factors may have affected pregnancy out-
comes, including the incidence of preeclampsia, despite
adjusting for 27 variables using a propensity score. More-
over, as we used secondary data, assessment of subfertility
was not possible, although it was reported to be associated
with an increased risk of preeclampsia [15,16]. To over-
come this limitation, a randomized controlled trial would
be ideal, but not feasible. Future studies will need to investi-
gate additional variables in order to better estimate the pro-
pensity score for undergoing IVF. Second, our study was
performed at a single tertiary perinatal center, although the
IVF patients were referred to the center from other fertility
clinics. Finally, our study only included pregnant Japanese
women. As such, we could not assess the effect of race on
the association between IVF and preeclampsia.
In conclusion, we found that IVF was weakly associ-
ated with preeclampsia when using propensity score
matching analysis (which provides a better estimate of
causality than adjusting for confounders) than when
using simple adjustments in multivariate logistic regres-
sion analysis. This suggests that the influence of the IVF
procedure itself was weaker than observed in previous
studies. Future studies with a larger study population
that can assess more confounding variables are needed
to replicate our findings.
Conclusions
Propensity score matching analysis revealed that the as-
sociation between IVF and preeclampsia became weaker
than with conventional adjustments in a multivariate lo-
gistic regression, suggesting that the association between
IVF and preeclampsia might be confounded by residual
unmeasured factors.
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